Enhancing Access to Lipid-Lowering Therapies and Optimizing Cholesterol Management in Very High-Risk Patients with ASCVD : Episode 7

Opinion

Video

May 14, 2024

Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.

EP: 1.How Often Do Patients with ASCVD Achieve Target LDL-C?

EP: 2.Gaps Between Guidelines and Clinical Practice Patterns in ASCVD

EP: 3.Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines

EP: 4.Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

EP: 5.Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD

EP: 6.Clinical Efficacy of Non-Statin Treatment Options in ASCVD

Now Viewing

EP: 7.Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

EP: 8.Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

EP: 9.The Role of Pharmacists in Treating Very High-Risk ASCVD

EP: 10.Valuable Metrics and Improving Adherence in Patients With ASCVD

EP: 11.Successful Collaborative Care Strategies for Pharmacists

Related Content

X-ray. ofheart -- Image credit: Anusorn | stock.adobe.com

December 13th 2024

FDA Expands Indication for Impella Heart Pumps to Include Pediatric Patients

Gillian McGovern, Assistant Editor

December 7th 2024

GLP1 Agonists and Dietary Fiber May Reduce VTE Risk and Improve GVHD Outcomes

Alana Hippensteele, Managing Editor

Block letters spelling POTS | Image Credit: © Fauzi - stock.adobe.com

December 3rd 2024

Patients With Post-COVID POTS Experience Disruptions in Circadian Blood Pressure Rhythm Regulation

Alexandra Gerlach, Associate Editor

December 2nd 2024

Before the Big Event: AI-Enabled Remote Cardiac Monitoring Can Mitigate Stress-Related Cardiovascular Events

Stuart Long

November 27th 2024

Aprocitentan: A New Hope in Resistant Hypertension Management

Kamila Dymala, PharmD, RPh, MBA, BCMTM, PACS

Cardiovascular Health, Atrial Fibrillation, FDA Approval | Image Credit: Sebastian Kaulitzki | stock.adobe.com

Published: November 27th 2024 | Updated: November 27th 2024

FDA Approves Landiolol For Treatment of Supraventricular Tachycardia

Ashley Gallagher, Associate Editor